Ben Goldacre writes about Glaxo’s, as well as the pharmaceutical industry’s, history of broken promises regarding access to clinical trial data.
Ben Goldacre writes about Glaxo’s, as well as the pharmaceutical industry’s, history of broken promises regarding access to clinical trial data.